TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Slides:

Advertisements

Similar presentations

All-Cause and Cause-Specific Mortality in Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study Meng-Sui Lee, Yi-Chun Yeh, Yun-Ting.

Advertisements

Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study Ingrid Snekvik, Catherine H. Smith,

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis Zenas Z.N. Yiu, Lesley S. Exton, Zarif.

Targeting the Plasticity of Psoriasis

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu,

IL-36γ Is Involved in Psoriasis and Allergic Contact Dermatitis

Emmanuel Contassot, Lars E. French

MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study Theodora Kanni, Maria Argyropoulou,

Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial Hywel C. Williams,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Expanding Our Understanding of Human Skin Aging

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists.

An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease Benjamin Ungar, Sandra Garcet, Juana Gonzalez, Nikhil.

Andrew Blauvelt, Mark G. Lebwohl, Robert Bissonnette

Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria Sarbjit S. Saini, Theodore A. Omachi, Benjamin.

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis Catharine.

Clinical Snippets Journal of Investigative Dermatology

Jean Claude Dusingize, Catherine M. Olsen, Nirmala P

Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept.

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis Howard Sofen, MD, Stacy.

Luigi Naldi Journal of Investigative Dermatology

Outcomes and Risk Factors in Patients with Multiple Primary Melanomas

The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031 David C.

A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea Emilie Sbidian, Éric Vicaut, Henri Chidiack,

Emmanuel Contassot, Lars E. French

Databases for Clinical Research

Joanne E. Sordillo, Peter Kraft, Ann Chen Wu, Maryam M. Asgari

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized,

Clinical Snippets Journal of Investigative Dermatology

Research Techniques Made Simple: Cost-Effectiveness Analysis

Targeting the Plasticity of Psoriasis

An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease Benjamin Ungar, Sandra Garcet, Juana Gonzalez, Nikhil.

Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases Megan H. Noe, Daniel B. Shin, Rebecca A. Hubbard,

Alexander Egeberg, Gregor B. E. Jemec, Alexa B

Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis” Kristian Reich, Craig Leonardi,

The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory.

Tamar Nijsten Journal of Investigative Dermatology

Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro Elizabeth S. Robinson, Paul Alves,

Francois le Pelletier, Anne Janin Journal of Investigative Dermatology

More Than Many: How to Manage the Most Frequent Cancer?

Minutes of the Board of Directors Meeting

Journal of Investigative Dermatology

Cancer Stem Cells in Squamous Cell Carcinoma

Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis Chloé Théréné, Emilie Brenaut, Thomas Barnetche,

IL-17 Takes Center Stage in Dermatophytosis

Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial.

Clinical Snippets Journal of Investigative Dermatology

Sigrun A.J. Schmidt, Serigne Lo, Loes M. Hollestein

Research Techniques Made Simple: Itch Measurement in Clinical Trials

Journal of Investigative Dermatology

Journal of Investigative Dermatology

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program Katherine Li, C. Chris Huang, Bruce Randazzo,

Michael C. Velarde Journal of Investigative Dermatology

Society for Investigative Dermatology 2010 Meeting Minutes

Journal of Investigative Dermatology

Staphylococcus epidermidis Sets Things Right Again

Erratum Journal of Investigative Dermatology

Research Snippets Journal of Investigative Dermatology

Reviewer Acknowledgment

BJD Editor’s Choice Journal of Investigative Dermatology

Cells to Surgery Quiz: February 2019

Journal of Investigative Dermatology

Tamar Nijsten, Diane Whalley, Joel Gelfand, David Margolis, Stephen P

Journal of Investigative Dermatology

Modification of the nail psoriasis severity index

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Presentation transcript:

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel, James G. Krueger, Marie-Claude Guertin, Malorie Chabot-Blanchet, Juana Gonzalez, Catherine Maari, Isabelle Delorme, Charles W. Lynde, Jean-Claude Tardif Journal of Investigative Dermatology Volume 137, Issue 8, Pages 1638-1645 (August 2017) DOI: 10.1016/j.jid.2017.02.977 Copyright © 2017 The Authors Terms and Conditions

Figure 1 CONSORT diagram. SAE, serious adverse event. Journal of Investigative Dermatology 2017 137, 1638-1645DOI: (10.1016/j.jid.2017.02.977) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Association between PASI at baseline and baseline cytokines levels. There was a significant positive correlation between PASI and serum levels of TNF-α, IL-17A, and S100A9 and a trend with IL-22. There was no significant correlation between PASI and serum levels of IL-6. PASI, Psoriasis Area and Severity Index. Journal of Investigative Dermatology 2017 137, 1638-1645DOI: (10.1016/j.jid.2017.02.977) Copyright © 2017 The Authors Terms and Conditions